1. Introduction {#s0005}
===============

The circadian system, controlled by the master circadian clock located in the suprachiasmatic nucleus (SCN) in the hypothalamus, plays a major role in regulating daily rhythms of sleep/wake cycle, central and peripheral tissue metabolism, and hormonal secretions ([@bib14]). The central clock is entrained by the light-dark cycle and other environmental factors, and relays the information via various pathways to the peripheral organs, leading to coordinated rhythms. In humans, it was estimated that ∼ 15% of all identified metabolites in plasma and saliva were under circadian control, especially plasma fatty acids and salivary amino acids ([@bib9]). Growing evidence has confirmed the detrimental effects of the disruption of circadian organization on metabolism. Experimental circadian misalignment in healthy human volunteers led to increased glucose levels, reduced insulin sensitivity, increased mean arterial blood pressure, reversal of daily cortisol rhythm, impaired autonomic function and elevated inflammatory markers (i.e. interleukin-10, interleukin-6, tumor necrosis factor-α, C-reactive protein) ([@bib6], [@bib18], [@bib37], [@bib49], [@bib27], [@bib28]). Cohort studies have also confirmed an association between shift work, usually associated with circadian misalignment, to an increase risk of incident diabetes ([@bib25], [@bib43]), with longer duration of shift work being associated with higher risk ([@bib31]).

Melatonin is a neurohormone secreted by a pineal gland during the biological night under the control of the central clock, and inhibited by light exposure ([@bib5]). Two G-protein coupled receptors, MT1 and MT2 (found in the SCN, brain tissues and peripheral tissues including pancreatic β-cells), mediate the effects of melatonin ([@bib32]). The 24 h rhythm of melatonin acts as an internal synchronizer of the circadian system ([@bib26]). In addition, melatonin has potent anti-oxidant and anti-inflammatory effects ([@bib21]). Data suggested that melatonin plays a role in glucose regulation. In a nested case control study within the Nurses' Health Study Cohort, women with the lowest tertile of nocturnal urinary 6-sulfatoxymelatonin (aMT6s, a major urine melatonin metabolite) to creatinine ratio had a significantly increased risk of diabetes development compared to those in the highest tertile (odds ratio 2.17) ([@bib23]). A cross sectional study of 513 elderly Japanese also found that high nocturnal urinary aMT6S (75th percentile vs 25th percentile) was associated with a 32% decrease in prevalent diabetes ([@bib29]). In addition, variants in the melatonin receptor type 1B (MTNR1B) have been shown to be associated with impaired fasting glucose and type 2 diabetes ([@bib42], [@bib4]). Moreover, 8--10 weeks of melatonin administration in diabetic rats resulted in reduction in glucose levels along with an improvement in insulin resistance ([@bib1], [@bib30]). These data support the possible beneficial effect of melatonin on glucose metabolism. However, administrations of immediate release melatonin in healthy women, both in the morning and evening, resulted in an increase in glucose response following glucose challenge, as compared to placebo ([@bib35]). This was related to decreased insulin secretion in the morning, and decreased insulin sensitivity in the evening. In another study of 14 postmenopausal women, 1 mg melatonin administered at 0800 h resulted in reduced glucose tolerance and insulin sensitivity as assessed by oral glucose challenge 45 min later ([@bib7]). These conflicting data highlight further research needed to clarify the role of melatonin in human's glucose metabolism.

The prevalence of diabetes is increasing in the U.S. and worldwide. Alarming statistics revealed that additional significant number of population have prediabetes, a state of abnormal glucose levels not yet meeting the criteria for diabetes ([@bib8]). These individuals, estimated at 86 million adults in the U.S. in 2012, are at high risk of developing diabetes ([@bib8]). Whether melatonin secretion is related to glucose metabolism in this population has not been studied. Besides traditional risk factors for diabetes, sleep disturbances \[i.e. insufficient sleep duration, poor sleep quality and obstructive sleep apnea (OSA)\] have been shown to be associated with metabolic dysfunction and increased risk of incident diabetes ([@bib3]). Some of these sleep disturbances were also found to be related to lower nocturnal aMT6S levels ([@bib36]). Therefore, this study was conducted with the aim to explore the relationship between nocturnal aMT6s and markers of glucose metabolism in patients with prediabetes, taken into consideration sleep related factors.

2. Material and methods {#s0010}
=======================

A cross-sectional study was conducted in non-shift working adults attending the outpatient department at the Faculty of Medicine Ramathibodi Hospital with a previous diagnosis of prediabetes defined as hemoglobin A1c (HbA1c) ≥ 5.70 to \< 6.50% ([@bib2]). Exclusion criteria included beta blocker use (known to affect melatonin secretion), being currently pregnant, a history of congestive heart failure or low ejection fraction, chronic obstructive pulmonary disease, end stage renal disease or severe chronic liver disease such as cirrhosis, stroke, permanent pacemaker placement, and use of certain medications (opioids/ narcotics, alpha adrenergic blockers, clonidine, methyldopa, nitroglycerin). The data utilized in this study were a part of those obtained from a larger cross-sectional study exploring the role of sleep duration and markers of glucose metabolism (clinicaltrials.gov, NCT02108197). All participants gave written informed consent. The protocol was approved by the Committee on Human Rights Related to Research Involving Human Subjects, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

After obtaining informed consent, weight and height were measured. Body mass index (BMI) was calculated as weight (kg)/height^2^ (m)^2^. The participants then underwent the following assessments, all performed within a two-week period.

2.1. Sleep duration and efficiency measurement {#s0015}
----------------------------------------------

Participants wore an Actiwatch 2 wrist activity monitor (Philips Respironics, Bend, Oregon) for 7 days. These monitors use highly sensitive omnidirectional accelerometers to count the number of wrist movements in 30-s epochs. The software scores each 30-s epoch as sleep or wake based on a threshold of activity counts that is estimated using activity within the epoch being scored as well as the epochs 2 min before and after that epoch. The participants were instructed to press the event marker button upon going to bed and awakening. Bedtime and wake time are set by the researcher using the event markers, a sleep log data as well as an in-person review of sleep timing with the participants upon return of the watch. Sleep duration was defined as the amount of actual sleep obtained at night, and sleep efficiency (a measure of sleep quality) was defined as percentage of time in bed spent sleeping. These two variables were calculated using Actiware 6.0 software, supplied by the manufacturer. Mid sleep time was defined as a midpoint between sleep start and sleep end. For each participant, the mean across all available nights was used. For 95% of participants in these analyses, at least 6 days of actigraphy recording were available and the remaining 5% had 5 days of actigraphy recording.

2.2. Assessment of OSA {#s0020}
----------------------

OSA was diagnosed using an FDA-approved portable diagnostic device, WatchPAT 200 (Itamar Medical, Israel), which has been validated against PSG in populations with and without diabetes ([@bib52], [@bib50]). This non-invasive device is shaped similar to a large watch, worn on the non-dominant wrist immediately before bedtime and removed upon awakening in the morning. The device has two probes connecting to the participants' fingers to measure changes in peripheral arterial tone (PAT) and oxygen saturation, along with a built-in actigraphy to measure sleep time. The severity of OSA is assessed by PAT Apnea Hypopnea Index (AHI) which is automatically generated by the software, using changes in the peripheral arterial tonometry. OSA is considered present if AHI ≥ 5. OSA is considered mild if AHI ≥ 5 but \< 15, moderate if AHI ≥15- 30, and severe if AHI \> 30.

Because this device relies on changes in peripheral arterial tone, use of certain medications including alpha-blockers and short acting nitrates, as well as permanent pacemaker, was not allowed according to the device's operation manual. In addition, it cannot differentiate obstructive from central apnea events. Therefore, we also excluded patients with certain conditions which may pose a higher risk for central apnea. These were described in the exclusion criteria.

2.3. Nocturnal urinary excretion of 6-sulfatoxymelatonin assessment {#s0025}
-------------------------------------------------------------------

The participants were instructed to discard the last void prior to bedtime and collect each subsequent void until the first next morning void. The samples were stored in a dark bottle at room temperature, the total volume measured, and then stored at -20C until assay. Urinary 6-sulfatoxymelatonin (aMT6s), a major melatonin metabolite, was measured by a competitive enzyme-linked immunosorbent assay (Bühlmann Laboratories AG, Schönenbuch, Switzerland). Urine creatinine was analyzed on an automated biochemical analyzer (Dimension RxL; Dade Behring, Newark, DE, USA). Urinary aMT6s/creatinine ratios were calculated by dividing urinary aMT6s levels by urine creatinine concentration, expressed as ng/mg, as previously described ([@bib23], [@bib22]). These values were referred to as nocturnal urinary aMT6s/Cr ratio. In addition, total urinary aMT6s was calculated from the concentration of aMT6s and urine volume.

2.4. Glucose, HbA1c and insulin measurements {#s0030}
--------------------------------------------

After an overnight fast, 75-gram glucose was given orally. Blood samples were obtained at 0 minutes for HbA1c, and at 0, 30, 60, 90, 120 min for glucose and insulin. Glucose and HbA1c were assayed in the clinical laboratory of Ramathibodi Hospital using hexokinase enzymatic method and turbid metric Inhibition Immunoassay, respectively. Serum insulin was measured by electrochemiluminescence immunoassay on a Cobas e 411 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The assays have intra-and inter-assay precision of 2.0% and 2.8%, respectively.

In addition, the following markers of glucose metabolism were calculated. Area under the curve (AUC) of glucose and insulin response to glucose challenge was calculated using the trapezoid rule. HOMA-IR, an index of fasting insulin resistance, was calculated using the formula \[fasting glucose (mg/dl)x fasting insulin (μU/ml)\]/405 ([@bib20]). The Insulinogenic Index, an estimate of early insulin secretion, was calculated by dividing increment in insulin during the first 30 min by the increment in glucose over the same period (ΔI~30~/ΔG~30~) ([@bib38]). The Matsuda index, an index of whole body insulin sensitivity, was calculated from the glucose and insulin levels during the glucose challenge as previously described ([@bib19]). Finally, the disposition index, an indicator of β-cell function adjusted for insulin sensitivity, was calculated as a product of the insulinogenic index and the Matsuda index ([@bib48]).

2.5. Statistical analysis {#s0035}
-------------------------

Data are expressed as mean (SD) or median (Interquartile range) or frequencies/percentages. Spearman's correlations were used to explore the associations between demographic, sleep variables, nocturnal urinary aMT6s/Cr ratio, and total nocturnal urinary aMT6s with markers of glucose metabolism. Multiple linear regression analyses were used to determine independent predictors of markers of glucose metabolism. Nocturnal urinary aMT6s/Cr ratio, total nocturnal urinary aMT6s, fasting insulin, AUC insulin, HOMA IR, Matsuda index, insulinogenic index and disposition index were not normally distributed, and therefore the natural logarithm (Ln) transformation of these variables was used in the regression analyses. All analyses were performed using SPSS 18.0 (Chicago, IL).

3. Results {#s0040}
==========

A total of 62 participants underwent the assessments. Their demographic, HbA1c levels, metabolic parameters in response to glucose challenge, sleep characteristics and nocturnal urinary aMT6s are shown in [Table 1](#t0005){ref-type="table"}. A majority (75%) of the participants were female with a mean age of 55 years and mean HbA1c level of 6.01%. OSA assessment was completed in 60 participants. An overall median AHI was 10.3 with 41 participants (69.4%) found to have OSA (40.3% with mild, 22.6% moderate, and 3.2% severe OSA, respectively). Mean sleep duration was 6.0 h/night.Table 1Demographic, glycemic, sleep and nocturnal urinary aMT6s in all participants.Table 1**Results (n = 62)*****[Demographic]{.ul}***Age (years)55.3 (8.2)Female (n)(%)47 (75.8%)BMI (kg/m^2^)26.7 (3.8)***[Glycemic characteristics]{.ul}***HbA1c (%)6.01 (0.20)Fasting glucose (mg/dl)101.8 (7.9)AUC glucose (mg/dl h)362 (59)Fasting insulin (μU/ml)11.6 (9.0, 17.8)AUC insulin (μU/ml h)215 (148, 294)HOMA IR2.86 (2.24, 4.95)Matsuda index2.04 (1.48, 2.92)Insulinogenic index0.90 (0.49, 1.25)Disposition index2.04 (1.48, 2.92)***[Sleep and urinary aMT6s]{.ul}***Nocturnal urinary aMT6s/ Cr ratio (ng/mg)17.4 (9.4, 28.2)Total nocturnal urinary aMT6s (ng)6256.5 (2878.6, 9546.2)AHI[a](#tbl1fna){ref-type="table-fn"}10.3 (3.6, 16.4)Sleep duration (min)359 (53)Sleep efficiency (%)83.4 (6.6)Mid sleep time (h)2:23 (0:47)[^1][^2]

[Table 2](#t0010){ref-type="table"} showed correlations between demographic, sleep, nocturnal urinary aMT6s/Cr ratio, total nocturnal urinary aMT6s and markers of glucose metabolism. Age and sex were not related to any glucose metabolism markers (p ≥ 0.05) while higher BMI significantly correlated with higher fasting insulin, AUC glucose and AUC insulin in response to glucose challenge, higher fasting insulin resistance (HOMA-IR) and higher whole body insulin resistance as indicated by lower Matsuda index. Shorter habitual sleep duration significantly correlated with higher HbA1c levels while none of the other sleep variables significantly correlated with any markers of glucose metabolism. Higher nocturnal urinary aMT6s/Cr ratio significantly correlated with lower fasting insulin (p = 0.004, [Fig. 1](#f0005){ref-type="fig"}) and lower AUC insulin response to glucose challenge (p = 0.027) but it was not correlated to fasting glucose, HbA1c or AUC glucose. In addition, higher nocturnal urinary aMT6s/Cr ratio significantly correlated with lower fasting and whole body insulin resistance as indicated by lower HOMA-IR (p = 0.006, [Fig. 2](#f0010){ref-type="fig"}) and higher Matsuda index (p = 0.011). None of the sleep variables (sleep duration, sleep efficiency and AHI), however, correlated with nocturnal urinary aMT6s/Cr ratio.Table 2Correlations between demographic, sleep, nocturnal urinary aMT6s and markers of glucose metabolism.Table 2**HbA1cFasting glucoseFasting insulinAUC glucoseAUC insulinHOMA IRMatsuda indexInsulinogenic indexDisposition indexAge***.064.028.149.116.152.135--.178.045-- .092***BMI***.178.082**.462***[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}***.257***[\*](#tbl2fnStar){ref-type="table-fn"}***.404***[\*\*](#tbl2fnStarStar){ref-type="table-fn"}***.443***[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}*--**.477***[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}*.121-- .197***Urinary aMT6s/Cr ratio***-- .108.000-- **.362***[\*\*](#tbl2fnStarStar){ref-type="table-fn"}*-- .071-- **.280***[\*](#tbl2fnStar){ref-type="table-fn"}*-- **.347***[\*\*](#tbl2fnStarStar){ref-type="table-fn"}***.319***[\*](#tbl2fnStar){ref-type="table-fn"}*− .163.106***Total urinary aMT6s***-- .072.036-- **.288***[\*](#tbl2fnStar){ref-type="table-fn"}*-- .046-- .243-- **.263***[\*](#tbl2fnStar){ref-type="table-fn"}***.257***[\*](#tbl2fnStar){ref-type="table-fn"}*-- .092.135***AHI***.159.055.204.122.139.211-- .207.067-- .104***Sleep duration***-- **.366***[\*\*](#tbl2fnStarStar){ref-type="table-fn"}*.114.168-- .160.112.157-- .127.193.088***Sleep efficiency***-- .169− .034-- .131-- .049.014-- .130.037--.019.053***Mid sleep time***-- .048-- .007.221-- .065.180.205-- .166.094-- .087*[^3][^4][^5]Fig. 1Correlation between nocturnal urinary aMT6s/Cr ratio and fasting insulin levels.Fig. 1Fig. 2Correlation between nocturnal urinary aMT6s/Cr ratio and HOMA-IR.Fig. 2

For total nocturnal urinary aMT6s, the relationships with markers of glucose metabolism were similar to those of nocturnal urinary aMT6s/Cr ratio. Higher total nocturnal urinary aMT6s was associated with lower fasting insulin (p = 0.023) and tended to be associated with lower AUC insulin response to glucose challenge (p = 0.057). In addition, higher total nocturnal urinary aMT6s significantly correlated with lower fasting and whole body insulin resistance (p = 0.039 and p = 0.044, respectively). Of note, nocturnal urinary aMT6s/Cr ratio was highly correlated with total nocturnal urinary aMT6s (correlation coefficient = 0.83, p \< 0.001).

Regression analyses to determine if nocturnal urinary aMT6s/Cr ratio independently predicts insulin levels or insulin resistance are shown in [Table 3](#t0015){ref-type="table"}. After adjusting for BMI, higher nocturnal urinary aMT6s was significantly associated with lower fasting insulin levels (B = − 0.180, p = 0.014) and lower fasting insulin resistance (HOMA-IR) (B = − 0.176, p = 0.025), while the relationship with AUC insulin and Matusda index was attenuated.Table 3Multiple regression analyses between nocturnal urinary aMT6s/Cr ratio and markers of glucose metabolism.Table 3**Fasting insulinAUC insulinHOMA IRMatsuda index**BP valueBP valueBP valueBP value**BMI**.060\< 0.001.0480.002.060\< 0.001*--* .060\< 0.001**Urinary aMT6s/Cr ratio***--* .1800.014*--* .1140.117*--* .1760.025.1340.069[^6]

[Table 4](#t0020){ref-type="table"} demonstrated regression analyses to determine if total nocturnal urinary aMT6s was independently associated with markers of glucose metabolism. The results were similar to those of nocturnal urinary aMT6s/Cr ratio. After adjusting for BMI, higher total nocturnal urinary aMT6s significantly correlated with lower fasting insulin levels (B = −0.133, p = 0.034), and borderline correlated with lower HOMA-IR (B = − 0.127, p = 0.057). We further explored by categorizing total nocturnal urinary aMT6s in to quartiles. After adjusting for BMI, those in the highest quartile of total nocturnal urinary aMT6s had significantly lower fasting insulin (B = − 0.139, p = 0.013) and lower HOMA-IR (B = − 0.130, p = 0.031) than those in the lowest quartile.Table 4Multiple regression analyses between total nocturnal urinary aMT6s and markers of glucose metabolism.Table 4**Fasting insulinAUC insulinHOMA IRMatsuda index**BP valueBP valueBP valueBP value**BMI**.0630.015.0490.002.063\< 0.001-- .062\< 0.001**Total nocturnal Urinary aMT6s**-- .1330.034-- .1100.075-- .1270.0591.7830.079

4. Discussion {#s0045}
=============

In this study of patients with prediabetes, we demonstrated that lower nocturnal secretion of aMT6s/Cr ratio, a major melatonin metabolite, was associated with higher degree of insulin resistance, as measured by HOMA-IR. Higher nocturnal urinary aMT6s/Cr ratio was associated with lower fasting insulin level but without any adverse effects on glucose levels. Similar results were demonstrated using total nocturnal urinary aMT6s. These data suggested that while nighttime melatonin may inhibit insulin secretion, it is associated with improved morning insulin sensitivity. The results support and further extend the knowledge regarding the role of melatonin in glucose metabolism.

The finding of the relationship between nocturnal urinary aMT6s level and insulin extends the findings in animal models of the antagonism between the two factors ([@bib33]). Both MT1 and MT2 are present in pancreatic islet. The inhibitory action of melatonin on insulin secretion is thought to be transmitted via a Gi protein signaling cascade, either involving cyclic adenosine monophosphate (cAMP) pathway (MT1 signaling), or cyclic guanosine monophosphate (cGMP) pathway (MT2 signaling) ([@bib33]). Thus, its action on insulin secretion may help maintain glucose levels overnight. In our population with prediabetes, despite being associated with lower insulin levels, higher nocturnal urinary aMT6s/Cr ratio was not associated with higher glucose levels, likely due to decreased insulin resistance as indicated by HOMA-IR. Our findings are in agreement with a study in 1,075 US women without diabetes which revealed that high nocturnal urinary aMT6S secretion was inversely associated with fasting insulin levels and insulin resistance ([@bib22]). Although both hepatic and peripheral insulin sensitivity contribute to HOMA-IR and Matsuda insulin sensitivity index, hepatic insulin sensitivity is thought to be an important determinant of HOMA-IR, especially in those with impaired glucose tolerance ([@bib46]), while Matsuda index represents whole-body insulin sensitivity ([@bib41]). As nocturnal urinary aMT6s in our study only borderline correlated with Matsuda insulin sensitivity index, this suggests that the relationship between urinary aMT6s and insulin sensitivity is more dependent upon hepatic insulin sensitivity. This is supported by several animal studies in which melatonin administration was associated with a reduction in HOMA-IR. Eight weeks of melatonin treatment in diabetic rats reduced hyperglycemia and insulin resistance as measured by HOMA-IR, as well as improved glucose uptake into adipocytes ([@bib30]). Another study in rats revealed that daily intraperitoneal administration of melatonin ameliorated insulin resistance associated with high fructose intake ([@bib15]). This could partly be due to reduction in hepatic gluconeogenesis and increased hypothalamic Akt phosphorylation as demonstrated by an intraventricular injection of melatonin in rats ([@bib11]). The authors suggested that melatonin activates hypothalamus-liver communication that may contribute to circadian adjustments of gluconeogenesis ([@bib11]). In addition, melatonin has been shown to regulate insulin sensitivity in adipocytes by enhancing the function of IRS-1 ([@bib39]), increase glycogen synthesis in hepatic cells ([@bib40]), and prevent mitochondrial dysfunction and insulin resistance in rat skeletal muscle ([@bib44]). Another potential mechanism in the association between melatonin and HOMA-IR could be related to the high oxidative state and free radicals generation seen in insulin resistance and hyperglycemia ([@bib51]). Melatonin has antioxidant properties and may act as a scavenger to change the redox state of the cells ([@bib51]). Collectively, these data support the role of melatonin in regulating glucose homeostasis. However, more human data are needed as the data derived from nocturnal animals that produce melatonin during their active phase while also consuming calories may not be completely applicable to the diurnal nature of humans.

Our data raise the question if melatonin administration may improve glucose metabolism in patients with prediabetes, a population at risk of developing diabetes. Diet, exercise, and metformin have been proven efficacious in diabetes prevention ([@bib16]). Interestingly, in a rat model of circadian disruption and diet-induced obesity, treatment with melatonin improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance while treatment with metformin alone improve insulin sensitivity and glucose tolerance but had no effects on circadian activity ([@bib45]). Melatonin and metformin, in combination, worked synergistically and resulted in improved adiposity, circadian activity, and reduced metabolic dysfunction ([@bib45]). A few studies have also explored the benefits of melatonin in humans. In a study of 30 patients with metabolic syndrome who did not respond to 3-month lifestyle intervention, 5 mg of melatonin two hour before bedtime for two months resulted in significantly improved blood pressure, reduced low density lipoprotein and increased antioxidative defense, while glucose levels did not change ([@bib17]). In another study, 44 obese women were randomized to receive 6 mg of melatonin two hour before bedtime or placebo for 40 days. Melatonin was associated with a significant reduction in inflammatory markers, including TNF-α and IL-6, compared to placebo, although glucose levels were not assessed ([@bib24]). Melatonin is also known to affect sleep, which in turn can affect glucose metabolism. In a randomized, double-blind, crossover study of 36 patients with type 2 diabetes and insomnia, three weeks of prolonged-release melatonin was associated with improved sleep but no changes in glucose levels were observed ([@bib13]). HbA1c levels, however, decreased significantly during the non-randomized extension phase but the reduction was not predicted by sleep improvements. Not all studies demonstrated benefits of melatonin. Acute melatonin administration (1 mg in the morning) in postmenopausal women resulted in reduced glucose tolerance and insulin sensitivity, compared to placebo, as assessed by an oral glucose tolerance test (OGTT) performed 45 minutes after melatonin ingestion ([@bib7]). Similarly, immediate release melatonin (5 mg) administration in healthy volunteer resulted in an increase in glucose response following an OGTT performed 15 min after the ingestion, as compared to placebo, both in the morning and the evening ([@bib35]). Timing of melatonin administration, formulary (immediate vs prolonged release) and duration of usage may play a role in different responses seen from various studies. Moreover, polymorphism in MTNR1B may play a role in the response to melatonin. In a study of 17 normoglycemic women, 5 mg of melatonin administered in the morning resulted in increased AUC glucose in response to OGTT, with the effects seen six times as large in those carrying MTNR1B genetic variant rs10830963 (known to be associated with type 2 diabetes risk) than in non-carriers ([@bib12]). In another study of 45 nondiabetic individuals, 23 with the risk allele (GG) of rs10830963 and 22 with non-risk allele (CC), 4 mg of melatonin before bedtime for 3 months resulted in a decrease in first-phase insulin release and an increase in glucose levels following an OGTT ([@bib47]). However, the changes were more pronounced in those with GG allele. Interestingly, insulin sensitivity also improved which may have contributed to the lowering of insulin secretion ([@bib47]). Therefore, melatonin action may be genotype specific. Future research in larger number of participants, especially those at risk of or with abnormal glucose metabolism, is needed to evaluate the effects of melatonin, possibly as an adjunct to lifestyle modifications, on glucose homeostasis and future diabetes risk.

To our knowledge, this is the first study exploring the relationship between nocturnal secretion of urinary aMT6s and markers of glucose metabolism in patients with prediabetes, along with comprehensive objective sleep assessments. However, there are limitations. We do not have the melatonin level at the time of the OGTT start. This could have influenced the results as melatonin was shown to acutely affect glucose tolerance ([@bib35], [@bib7]), and that insulin sensitivity worsened the longer melatonin levels remained high after wake time ([@bib10]). The cross sectional design did not allow us to determine the direction of causality in the associations found. Despite being associated with higher HOMA-IR, lower nocturnal urinary aMT6s was not associated with higher glucose levels. This was in contrast to a previous small study which found that lower urinary aMT6s was related to higher HbA1c levels in patients with type 2 diabetes ([@bib34]). This difference could possibly be due to the narrower range of glucose levels in this patient group, compare to those with type 2 diabetes, and the ability of the β-cell to compensate for insulin resistance as their disease is in its early stage. In contrast to the previous study, we did not find the relationship between sleep variables (sleep duration and efficiency) and nocturnal urinary aMT6s ([@bib36]). The reason for this is unclear but the relatively small number of participants in the current study may play a role. Lastly, sleep variables were obtained using actigraphy and WatchPAT instead of the gold standard polysomnography in this study.

In conclusion, lower nocturnal secretion of urinary aMT6s inversely associated with insulin resistance and insulin levels in patients with prediabetes. These results support the role of melatonin in glucose metabolism.
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[^1]: Data are expressed as mean (SD) or median (interquartile range).

[^2]: n = 60.

[^3]: p \< 0.05.

[^4]: p \< 0.01.

[^5]: p \< 0.001.

[^6]: B = unstandardized coefficient.
